Physician profile
Jack Cossman
NPI 1912318304
$4,738.15
in general payments reported to CMS, 2019-2025
26 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $235 · 2021: $477 · 2022: $180 · 2023: $582 · 2024: $416 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.24 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $638.09 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $541.54 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $527.44 | 2021-2025 | Opzelura |
| Abbvie INC. | $496.23 | 2019-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $350.28 | 2019-2025 | Dupixent |
| Organon LLC | $324.45 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $229.31 | 2024-2025 | |
| Dermavant Sciences, INC. | $201.07 | 2023 | Vtama |
| Ucb, INC. | $191.90 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $161.14 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $148.12 | 2023-2025 | Zoryve |
| Genzyme Corporation | $136.85 | 2021-2023 | |
| Amgen INC. | $125.87 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $88.45 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $83.17 | 2023-2025 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $72.83 | 2020-2022 | |
| Lilly USA, LLC | $69.97 | 2020-2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $62.66 | 2020-2025 | |
| Leo Pharma INC. | $53.25 | 2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $46.43 | 2020 | |
| Merz North America, INC. | $45.58 | 2021 | |
| Celgene Corporation | $42.07 | 2019 | |
| Vyne Pharmaceuticals INC. | $39.45 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.23 | 2025 | Cabtreo |
| Lnhc, INC | $21.97 | 2025 | Zelsuvmi |
| Epi Health, LLC | $17.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.